보고서 정보
주관연구기관 |
(주)동방 |
보고서유형 | 최종보고서 |
발행국가 | 대한민국 |
언어 |
한국어
|
발행년월 | 2012-12 |
과제시작연도 |
2011 |
주관부처 |
농림축산식품부 Ministry of Agriculture, Food and Rural Affairs(MAFRA) |
등록번호 |
TRKO201400026450 |
과제고유번호 |
1545003027 |
사업명 |
생명산업기술개발 |
DB 구축일자 |
2014-11-14
|
DOI |
https://doi.org/10.23000/TRKO201400026450 |
초록
▼
○ 연구결과
국내에서 빈번하게 발생하는 연쇄상 구균과 흉막폐렴균의 혈청형을 분석하여, 국내 실정에 적합한 연쇠상 구균증 예방 백신과 백신 접종 프로그램을 개발하였고, 첨단기법을 통한 마이코 플라즈마균을 삽입한 흉막폐렴균을 이용하여 흉막폐렴과 마이코플라즈마성 폐렴을 동시에 예방할 수 있는 다중점 백신주를 개발하였다. 즉, 본 연구 개발에서는 양돈 산업에 큰 피해를 주는 두 호흡기 질환 세균을 동시에 방어하기 위한 재조합 단백질을 개발하였다. 이를 위하여 흉막폐렴균이 분비하는 Apx toxin 단백질 중 일부 면역원성이 크고 E.
○ 연구결과
국내에서 빈번하게 발생하는 연쇄상 구균과 흉막폐렴균의 혈청형을 분석하여, 국내 실정에 적합한 연쇠상 구균증 예방 백신과 백신 접종 프로그램을 개발하였고, 첨단기법을 통한 마이코 플라즈마균을 삽입한 흉막폐렴균을 이용하여 흉막폐렴과 마이코플라즈마성 폐렴을 동시에 예방할 수 있는 다중점 백신주를 개발하였다. 즉, 본 연구 개발에서는 양돈 산업에 큰 피해를 주는 두 호흡기 질환 세균을 동시에 방어하기 위한 재조합 단백질을 개발하였다. 이를 위하여 흉막폐렴균이 분비하는 Apx toxin 단백질 중 일부 면역원성이 크고 E. coli 내 발현이 용이하다고 판단되는 N-terminal의 일부를 선택하여 재조합 단백질 ApxN을 E. coli를 이용하여 발현하였고 마이코 플라즈마균의 P97 단백질에서 면역원성이 크다고 판단되는 C-terminal 부위에 해당하는 재조합 단백질 P97C를 유사한 방법으로 발현하였다. 또 두 재조합 단백질의 융합 (fusion) 단백질 Ap97도 발현하였다. 재조합 단백질 P97C와 Ap97제작에 있어서는 P97 유전자 상에 존재하는 stop codon을 제거하고 E. coli에서의 발현을 고효율화 할 목적으로 유전자 서열을 최적화하여 사용하였다.
개발된 재조합 단백질의 면역원성을 확인하기 위하여 각각 단백질을 실험동물 마우스에 투여하여 면역반응양태를 분석하였다. 또, 형성되는 항혈청이 각각의 해당 미생물 단백질을 인지할 수 있는지 여부를 분석하여, 개발된 재조합 단백질 투여에 의하여 두 가지 돼지호흡기 질병 예방 효과 가능성을 확인하였다.
Abstract
▼
The purpose of this research is the development of multi-point vaccine for Streptococcus suis, Actinobacillus pleuropneumoniae, Mycoplasma hyopneumoniae-Actionbacillus pleuropneumoniae that has recently caused trouble for bacterial wasting disease in Korean pig farms. There is a difficulty for preve
The purpose of this research is the development of multi-point vaccine for Streptococcus suis, Actinobacillus pleuropneumoniae, Mycoplasma hyopneumoniae-Actionbacillus pleuropneumoniae that has recently caused trouble for bacterial wasting disease in Korean pig farms. There is a difficulty for prevention of the disease because there is no preventive monovalent vaccine for bacterial wasting disease by S. suis in Korean farms. Also, because most of preventive vaccine for A. pleuropneumoniae and M. hyopneumoniae are imported and the purchasing cost of medicine in Korean pig farms has been increased. Therefore, we tried to overcome these problems by developing the vaccine for the bacterial wasting disease that cause the biggest trouble in Korean pig farms. In the case of M. hyopneumoniae, having difficulty in isolation, we tried to develop the multivalent M. hyopneumoniae-A. pleuropneumoniae vaccine using the newest biotechnologic method. The main adhesion gene is inserted into A. pleuropneumoniae and produces the hybrid bacteria of M.
hyopneumoniae-A. pleuropneumoniae. That is, for periods of up to four years of research we tried to develop the vaccine and vaccination program for S. suis and A. pleuropneumoniae making a thorough investigation of the serotype of S. suis and A. pleuropneumoniae with frequency adequate for Korean field conditions. Also, through the newest biotechnologic method of insertion of M. hyopneumoniae into A. pleuropneumoniae and development of the multi-point vaccine, we placed priority to develop the vaccine strain to prevent pneumonia caused by both M. hyopneumoniae and A. pleuropneumoniae.
The industrialization way of the vaccine that we tried to develop can be set easily by the domestic and foreign market analysis. The direction of this research is that production of the vaccine necessary for the pig farms and efficacy-maximizing vaccine. And we have to plan the industrialization of the vaccine preventing the bacterial wasting disease by S. suis by the end of this research, the feature of the vaccine produced in this research is divided into main two features; prevention of wasting disease and accordance of antigen of the vaccine with the serotype that has occurred in Korean farms. The streptococcal vaccine that has come into the market is the preventive vaccine for neurological signs and symptoms by meningitis looking the efficacy from the side. However, the vaccine that will be produced in this research has the preventive purpose for pericarditis, pleurisy, peritonitis and will protect the pigs from the wasting disease. The vaccine made from this research has outstanding feature for a field application because it contains the serotype of the bacteria causing the wasting disease in domestic farms looking the ingredients of a product. In case of the Streptococcus suis vaccine, we have the plan of vaccination program for both the sows and weaned pigs before the vaccine sale, it can induce the enough demand industrially, considering sow and young pig population.
The features of the vaccine for A. pleuropneumoniae, that is made from this research, are divided into three characteristics. It contains maximization of immunity for the antigen, serotype appropriate in domestic issue, and minimization of the side effect. That is, it contains outer membranous proteins of A. pleuropneumoniae that have outstanding immunity and distinguish itself than other vaccines. Also, it can protect over 95% of serotypes of A. pleuropneumoniae occurred in Korean farms because it contains serotypes 2 and 5 that occurred frequently in domestic farms, and serotype 6 which cause the problem recently, as well. And most of the vaccine for A. pleuropneumoniae have the side effect than other vaccines for different infectious agent, but we add a special reinforcing agent and minimize the side effect and avoiding situation in domestic farms.
The vaccine for haemophilus pleuropneumoniae that is produced from this research is scheduled for vaccinaton twice at the age of fifth week and eighth week. And it has enough market potential because the vaccination target for yearly quantity of pigs are 13 million in domestic farms.
In the case of the preventive multi-point vaccine for M. hyopneumoniae-A. pleuropneumoniae, it has two main features that completely differ from the existing vaccine. One is the maximization of efficacy of the vaccine, and the other is reliability and economic feasibility of usage. Currrently, even though foreign vaccine companies are selling M. hyopneumoniae and A. pleuropneumoniae vaccines respectively, the combined vaccine are not sold in the market because there are many problems.
To resolve this problem, we maximized the efficacy of the vaccine by completely combining two kinds of bacteria. In realistic terms, the vaccine that will be produced from this research has two features of reliability and economic feasibility of usage because it has the characteristics of two kinds of vaccines at a time. This will reduce labor in many farms.
The combined vaccine for M. hyopneumoniae-A. pleuropneumoniae is targeted for one shot vaccination. It satisfies the efficacy, convenience, economic properties and eventually creates sufficient industrial demands.
Therefore, through this research we developed and merchandised a unique combined M. hyopneumoniae-A. pleuropneumoniae in the world, making it possible to hold a large domestic market share, the possibility for overseas market, sales increase of domestic vaccine maker, and the decrease of the economic burden on farmers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.